Zobrazeno 1 - 10 of 241 pro vyhledávání: '"Poulsen TT"'
1
Akademický článek
miR‐4448/Girdin/Akt/AMPK axis inhibits EZH2‐mediated EMT and tumorigenesis in small‐cell lung cancer.
Autor: Koyama, Nobuyuki1 (AUTHOR) nkoyama@saitama‐med.ac.jp, Ishikawa, Yuichi2 (AUTHOR), Ohta, Hiromitsu3 (AUTHOR), Aoki, Takuya4 (AUTHOR), Kyoyama, Hiroyuki1 (AUTHOR), Aoshiba, Kazutetsu5 (AUTHOR), Uematsu, Kazutsugu1 (AUTHOR)
Publikováno v: Cancer Medicine. Oct2024, Vol. 13 Issue 19, p1-13. 13p.
Zobrazit plný text záznamu
2
Akademický článek
PD-L1 siRNA hitched polyethyleneimine-elastase constituting nanovesicle induces tumor immunogenicity and PD-L1 silencing for synergistic antitumor immunotherapy.
Autor: Du, Li1,2 (AUTHOR), Gong, Yao1 (AUTHOR), Zhang, Xiaoying1 (AUTHOR), Sun, Jide3 (AUTHOR), Gao, Fengxia1 (AUTHOR), Shen, Meiying4 (AUTHOR), Bai, Huili1 (AUTHOR), Yang, Tiantian1 (AUTHOR), Cheng, Xiaoxue1 (AUTHOR), Li, Siqiao5 (AUTHOR), Peng, Jian2 (AUTHOR), Liu, Zhangling2 (AUTHOR), Ding, Shijia6 (AUTHOR), Chen, Junman6 (AUTHOR) junman816@163.com, Cheng, Wei1,2 (AUTHOR) chengwei@hospital.cqmu.edu.cn
Publikováno v: Journal of Nanobiotechnology. 7/27/2024, Vol. 22 Issue 1, p1-20. 20p.
Zobrazit plný text záznamu
3
Akademický článek
HER-Family Ligands Promote Acquired Resistance to Trastuzumab in Gastric Cancer.
Autor: Sampera A; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain., Sánchez-Martín FJ; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain., Arpí O; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain., Visa L; Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain., Iglesias M; Department of Pathology, Hospital del Mar, Barcelona, Spain.; Universitat Autonoma de Barcelona, Spain., Menéndez S; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain., Gaye É; Oncologie Médicale, Institut de Cáncerologie et Hématologie, Morvan, Brest, France., Dalmases A; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain., Clavé S; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain.; Department of Pathology, Hospital del Mar, Barcelona, Spain., Gelabert-Baldrich M; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain., Poulsen TT; Symphogen A/S, Ballerup, Denmark., Kragh M; Symphogen A/S, Ballerup, Denmark., Bellosillo B; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain.; Department of Pathology, Hospital del Mar, Barcelona, Spain., Albanell J; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain.; Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain.; Universitat Pompeu Fabra, Barcelona, Spain., Rovira A; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain.; Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain., Montagut C; Cancer Research Program, Institut Hospital del Mar d'Investigacions Mèdiques (IMIM)-CIBERONC, Barcelona, Spain. cmontagut@hospitaldelmar.cat.; Department of Medical Oncology, Hospital del Mar-CIBERONC, Barcelona, Spain.; Universitat Pompeu Fabra, Barcelona, Spain.
Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2019 Nov; Vol. 18 (11), pp. 2135-2145. Date of Electronic Publication: 2019 Sep 04.
Zobrazit plný text záznamu
4
Akademický článek
CD4 + and CD8a + PET imaging predicts response to novel PD-1 checkpoint inhibitor: studies of Sym021 in syngeneic mouse cancer models.
Autor: Kristensen LK; Minerva Imaging, Copenhagen, Denmark.; Dept. of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Dept. of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Denmark., Fröhlich C; Symphogen A/S, Ballerup, Denmark., Christensen C; Minerva Imaging, Copenhagen, Denmark.; Dept. of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Dept. of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Denmark., Melander MC; Symphogen A/S, Ballerup, Denmark., Poulsen TT; Symphogen A/S, Ballerup, Denmark., Galler GR; Symphogen A/S, Ballerup, Denmark., Lantto J; Symphogen A/S, Ballerup, Denmark., Horak ID; Symphogen A/S, Ballerup, Denmark., Kragh M; Symphogen A/S, Ballerup, Denmark., Nielsen CH; Minerva Imaging, Copenhagen, Denmark.; Dept. of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Dept. of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Denmark., Kjaer A; Dept. of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Dept. of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Denmark.
Publikováno v: Theranostics [Theranostics] 2019 Oct 18; Vol. 9 (26), pp. 8221-8238. Date of Electronic Publication: 2019 Oct 18 (Print Publication: 2019).
Zobrazit plný text záznamu
5
Akademický článek
Acquired Resistance to a MET Antibody In Vivo Can Be Overcome by the MET Antibody Mixture Sym015.
Autor: Pollmann SE; Symphogen A/S, Ballerup, Denmark. sel@symphogen.com., Calvert VS; Center for Applied Proteomics and Molecular Medicine, George Mason University, Virginia., Rao S; Innovation Center for Biomedical Informatics, Georgetown University, Washington DC., Boca SM; Innovation Center for Biomedical Informatics, Georgetown University, Washington DC., Madhavan S; Innovation Center for Biomedical Informatics, Georgetown University, Washington DC., Horak ID; Symphogen A/S, Ballerup, Denmark., Kjaer A; Department of Clinical Physiology, Nuclear Medicine & PET and Cluster for Molecular Imaging, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark.; Department of Biomedical Sciences, Rigshospitalet and University of Copenhagen, Copenhagen, Denmark., Petricoin EF; Center for Applied Proteomics and Molecular Medicine, George Mason University, Virginia., Kragh M; Symphogen A/S, Ballerup, Denmark., Poulsen TT; Symphogen A/S, Ballerup, Denmark.
Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2018 Jun; Vol. 17 (6), pp. 1259-1270. Date of Electronic Publication: 2018 Mar 15.
Zobrazit plný text záznamu
6
Akademický článek
Efficacy of Sym004 in Patients With Metastatic Colorectal Cancer With Acquired Resistance to Anti-EGFR Therapy and Molecularly Selected by Circulating Tumor DNA Analyses: A Phase 2 Randomized Clinical Trial.
Autor: Montagut C; Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain., Argilés G; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Ciardiello F; Seconda Università degli Studi di Napoli, Naples, Italy., Poulsen TT; Symphogen A/S, Ballerup, Denmark., Dienstmann R; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain., Kragh M; Symphogen A/S, Ballerup, Denmark., Kopetz S; Department of Gastrointestinal Medical Oncology, University of Texas MD Anderson Cancer Center, Houston., Lindsted T; Symphogen A/S, Ballerup, Denmark., Ding C; Symphogen A/S, Ballerup, Denmark., Vidal J; Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain., Clausell-Tormos J; Symphogen A/S, Ballerup, Denmark., Siravegna G; Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.; FIRC Institute of Molecular Oncology (IFOM), Milan, Italy., Sánchez-Martín FJ; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain., Koefoed K; Symphogen A/S, Ballerup, Denmark., Pedersen MW; Symphogen A/S, Ballerup, Denmark., Grandal MM; Symphogen A/S, Ballerup, Denmark., Dvorkin M; BHI of Omsk Region 'Clinical Oncology Dispensary,' Omsk, Russia., Wyrwicz L; Centrum Onkologii-Instytut im. M. Sklodowskiej Curie, Warsaw, Poland., Rovira A; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain., Cubillo A; Centro Integral Oncologico Clara Campa, Madrid, Spain., Salazar R; Institut Català d'Oncologia, Institut d'Investigació biomèdica de Bellvitge, CIBERONC, Barcelona, Spain., Desseigne F; Consultation d'Oncologie Génétique, Centre de Lutte Contre le Cancer Leon Berard, Lyon, France., Nadal C; Hospital Clinic of Barcelona, University of Barcelona, Spain., Albanell J; Medical Oncology Department, Hospital del Mar-CIBERONC, Barcelona, Spain.; Cancer Research Program, IMIM (Hospital del Mar Research Institute), Barcelona, Spain.; Pompeu Fabra University, Barcelona, Spain., Zagonel V; Medical Oncology Unit 1, Istituto Oncologico Veneto, IRCCS, Padova, Italy., Siena S; Grande Ospedale Metropolitano Niguarda and Università degli Studi di Milano, Milano, Italy., Fumi G; Azienda Ospedaliera S. Maria Di Terni, Terni, Italy., Rospo G; Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy., Nadler P; Symphogen A/S, Ballerup, Denmark., Horak ID; Symphogen A/S, Ballerup, Denmark., Bardelli A; Candiolo Cancer Institute-FPO, IRCCS, Candiolo, Torino, Italy.; University of Torino, School of Medicine, Torino, Italy., Tabernero J; Medical Oncology Department, Vall d'Hebron University Hospital, Barcelona, Spain.; Institute of Oncology (VHIO), Universitat Autònoma de Barcelona, CIBERONC, Barcelona, Spain.
Publikováno v: JAMA oncology [JAMA Oncol] 2018 Apr 12; Vol. 4 (4), pp. e175245. Date of Electronic Publication: 2018 Apr 12.
Zobrazit plný text záznamu
7
Akademický článek
Simultaneous Targeting of Two Distinct Epitopes on MET Effectively Inhibits MET- and HGF-Driven Tumor Growth by Multiple Mechanisms.
Autor: Grandal MM; Symphogen A/S, Ballerup, Denmark. mvg@symphogen.com., Havrylov S; McGill University, Montreal, Quebec, Canada., Poulsen TT; Symphogen A/S, Ballerup, Denmark., Koefoed K; Symphogen A/S, Ballerup, Denmark., Dahlman A; Symphogen A/S, Ballerup, Denmark., Galler GR; Symphogen A/S, Ballerup, Denmark., Conrotto P; Symphogen A/S, Ballerup, Denmark., Collins S; Symphogen A/S, Ballerup, Denmark., Eriksen KW; Symphogen A/S, Ballerup, Denmark., Kaufman D; Van Andel Research Institute, Grand Rapids, Michigan., Woude GFV; Van Andel Research Institute, Grand Rapids, Michigan., Jacobsen HJ; Symphogen A/S, Ballerup, Denmark., Horak ID; Symphogen A/S, Ballerup, Denmark., Kragh M; Symphogen A/S, Ballerup, Denmark., Lantto J; Symphogen A/S, Ballerup, Denmark., Bouquin T; Symphogen A/S, Ballerup, Denmark., Park M; McGill University, Montreal, Quebec, Canada., Pedersen MW; Symphogen A/S, Ballerup, Denmark.
Publikováno v: Molecular cancer therapeutics [Mol Cancer Ther] 2017 Dec; Vol. 16 (12), pp. 2780-2791. Date of Electronic Publication: 2017 Aug 11.
Zobrazit plný text záznamu
8
Akademický článek
Sym015: A Highly Efficacious Antibody Mixture against MET -Amplified Tumors.
Autor: Poulsen TT; Symphogen A/S, Ballerup, Denmark., Grandal MM; Symphogen A/S, Ballerup, Denmark., Skartved NJØ; Symphogen A/S, Ballerup, Denmark., Hald R; Symphogen A/S, Ballerup, Denmark., Alifrangis L; Symphogen A/S, Ballerup, Denmark., Koefoed K; Symphogen A/S, Ballerup, Denmark., Lindsted T; Symphogen A/S, Ballerup, Denmark., Fröhlich C; Symphogen A/S, Ballerup, Denmark., Pollmann SE; Symphogen A/S, Ballerup, Denmark., Eriksen KW; Symphogen A/S, Ballerup, Denmark., Dahlman A; Symphogen A/S, Ballerup, Denmark., Jacobsen HJ; Symphogen A/S, Ballerup, Denmark., Bouquin T; Symphogen A/S, Ballerup, Denmark. ttp@symphogen.com., Pedersen MW; Symphogen A/S, Ballerup, Denmark., Horak ID; Symphogen A/S, Ballerup, Denmark., Lantto J; Symphogen A/S, Ballerup, Denmark., Kragh M; Symphogen A/S, Ballerup, Denmark.
Publikováno v: Clinical cancer research : an official journal of the American Association for Cancer Research [Clin Cancer Res] 2017 Oct 01; Vol. 23 (19), pp. 5923-5935. Date of Electronic Publication: 2017 Jul 05.
Zobrazit plný text záznamu
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Pan-HER-An antibody mixture targeting EGFR, HER2 and HER3 abrogates preformed and ligand-induced EGFR homo- and heterodimers.
Autor: Ellebaek S; Symphogen A/S, Ballerup, Denmark., Brix S; Center for Biological Sequence Analysis, Department of Systems Biology, Technical University of Denmark, Kongens Lyngby, Denmark., Grandal M; Symphogen A/S, Ballerup, Denmark., Lantto J; Symphogen A/S, Ballerup, Denmark., Horak ID; Symphogen A/S, Ballerup, Denmark., Kragh M; Symphogen A/S, Ballerup, Denmark., Poulsen TT; Symphogen A/S, Ballerup, Denmark.
Publikováno v: International journal of cancer [Int J Cancer] 2016 Nov 01; Vol. 139 (9), pp. 2095-105. Date of Electronic Publication: 2016 Jul 19.
Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje